SNTI logo

Senti Biosciences, Inc. Common Stock


SNTI: Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.


Show SNTI Financials

Consumer Interest
SEC Filings

Recent trades of SNTI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by SNTI's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Combinatorial cancer immunotherapy Sep. 20, 2022
  • Patent Title: Combinatorial cancer immunotherapy Aug. 23, 2022
  • Patent Title: Combinatorial cancer immunotherapy May. 04, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of SNTI in WallStreetBets Daily Discussion


Recent insights relating to SNTI

CNBC Recommendations

Recent picks made for SNTI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SNTI

Corporate Flights

Flights by private jets registered to SNTI